Does Affinity Health Plan Cover Vyvanse?

What Is Affinity Health Plan and How Does Its Drug Coverage Work?

Affinity Health Plan is a New York-based managed-care organization primarily serving Medicaid, Child Health Plus, and Essential Plan enrollees across New York City and surrounding counties. The plan administers a pharmacy benefit that follows a tiered formulary reviewed annually. Coverage decisions for brand-name Schedule II stimulants like Vyvanse sit at the intersection of formulary policy, prior authorization requirements, and state Medicaid rules.

Plan Types That Affect Coverage

Affinity operates several distinct product lines, and the formulary differs by product.

• Medicaid Managed Care: Follows New York State Medicaid preferred drug list (PDL). Generic stimulants are typically preferred. New York State Medicaid covers ADHD pharmacotherapy when DSM-5 criteria are met and documentation requirements are satisfied. [1]
• Essential Plan: A lower-cost product for adults earning 138-200% of the federal poverty level. Formulary mirrors the Medicaid PDL in most respects.
• Child Health Plus: Covers enrollees up to age 19. ADHD is among the most common childhood diagnoses, affecting approximately 9.8% of U.S. Children aged 3-17 per CDC data. [2]
• Commercial Exchange Plans: If Affinity offers a QHP on the New York State of Health exchange, formulary rules differ from Medicaid and may allow broader brand coverage.

Confirming which product you hold is the first step. Check the top of your insurance card.

How the Formulary Tier System Works

Affinity, like most managed-care plans, uses a 4-to-5-tier formulary. Tier 1 drugs carry the lowest copay (often $0-$3 for Medicaid). Tier 3 and Tier 4 drugs carry higher cost-sharing or require prior authorization. Brand-name Vyvanse historically sits at Tier 3 or Tier 4. The 2023 launch of generic lisdexamfetamine dimesylate by multiple manufacturers changed the calculus: most plans moved to prefer the generic at a lower tier. [3]

What Is Vyvanse and Why Is It Prescribed?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a prodrug that converts to d-amphetamine after absorption. The FDA first approved it in 2007 for ADHD in adults and children aged 6 and older, then in 2015 for moderate-to-severe binge eating disorder (BED) in adults. [4]

ADHD Indication

The DSM-5 requires at least six inattentive or hyperactive-impulsive symptoms (five for adults age 17 and older), present before age 12, in two or more settings, causing functional impairment. [5] Insurance plans, including Affinity, typically require documentation confirming this diagnostic standard before approving any stimulant.

In the key Phase 3 trial supporting Vyvanse's adult ADHD approval, lisdexamfetamine 30-70 mg/day produced statistically significant reductions in ADHD Rating Scale IV total scores versus placebo at week 4 (P<0.001). [6] That trial enrolled 420 adults, and 56% of lisdexamfetamine-treated patients were rated "much improved" or "very much improved" on the Clinical Global Impression scale versus 19% on placebo. [6]

Binge Eating Disorder Indication

The FDA approved lisdexamfetamine 50 mg and 70 mg for moderate-to-severe BED in adults in January 2015. [4] Coverage for BED is more variable across Medicaid plans than ADHD coverage. Some state Medicaid programs restrict the BED indication entirely; others require documentation of failed behavioral therapy.

Schedule II Classification

Because lisdexamfetamine is a Schedule II controlled substance under the Controlled Substances Act, prescriptions cannot be called in by phone and require a new written or e-prescribe authorization for each 30-day supply. [7] Insurers applying prior authorization to Schedule II stimulants must comply with these additional dispensing constraints.

Prior Authorization for Vyvanse: What Affinity Typically Requires

Prior authorization (PA) is the process by which a plan reviews clinical documentation before agreeing to pay for a drug. For brand-name Vyvanse on Affinity Health Plan, PA is almost always required. Even for generic lisdexamfetamine, some plans require PA or step therapy.

Typical PA Criteria

PA criteria for Vyvanse-class medications on Medicaid managed-care plans generally include: [8]

1. A confirmed DSM-5 ADHD diagnosis from a licensed psychiatrist, psychologist, or primary care physician.
2. Documentation of age-appropriate symptom severity (ADHD Rating Scale score, Conners rating, or equivalent).
3. Evidence of functional impairment in at least two settings (home and school, or home and work).
4. Trial and failure, or medical contraindication to, at least one preferred first-line stimulant. This is the step therapy requirement discussed below.
5. Prescriber attestation that the patient is not at elevated cardiovascular risk inconsistent with stimulant use.

The American Academy of Child and Adolescent Psychiatry (AACAP) 2007 Practice Parameter, updated with subsequent guidance, states that "stimulant medications are the most effective treatment for ADHD and should be offered as first-line pharmacotherapy." [9] Plans use this same evidence base to justify requiring generic stimulants before brand Vyvanse.

Step Therapy: The Most Common Coverage Barrier

Step therapy requires a patient to try one or more preferred (lower-cost) drugs before the plan will cover a non-preferred option. For Vyvanse, the typical step sequence on Medicaid plans is:

• Step 1: Generic mixed amphetamine salts (generic Adderall), 5-30 mg, trialed for at least 4 weeks.
• Step 2: Generic methylphenidate (generic Ritalin or Concerta), if amphetamine salts failed.
• Step 3: Lisdexamfetamine (generic Vyvanse) or brand Vyvanse, if both steps failed or are contraindicated.

A prescriber can request a step-therapy exemption if the patient has a documented history of adverse effects, a clinical reason a specific formulation is medically necessary, or prior treatment failure outside the current plan. New York State enacted the "Step Therapy Reform Act" (effective January 2017), which requires health plans to grant exceptions when step therapy is clinically inappropriate. [10]

Submitting the PA Request

The prescriber, not the patient, submits most PA requests. The typical workflow:

1. The pharmacy runs the claim and receives a rejection with a prior authorization required code.
2. The pharmacy notifies the prescriber's office.
3. The prescriber submits a PA form to Affinity (via fax, phone, or electronic PA portal).
4. Affinity has up to 3 business days (or 72 hours for urgent requests) to respond under federal Medicaid managed-care rules. [8]
5. Approval generates an authorization number attached to the member's claim.

Generic Lisdexamfetamine: The Coverage Field After 2023

The entry of generic lisdexamfetamine dimesylate in August 2023 changed what insurers will cover first. Multiple manufacturers, including Amneal Pharmaceuticals and Teva, received FDA approval for generic versions. [3]

Price Difference

Brand Vyvanse carries a wholesale acquisition cost (WAC) exceeding $400 per 30-day supply for most doses. Generic lisdexamfetamine dimesylate retails at $60-$120 per 30-day supply at major pharmacy chains, depending on dose and pharmacy. For Medicaid enrollees, cost-sharing is often $0-$3 regardless of tier, but PA and step therapy requirements still apply.

Therapeutic Equivalence

The FDA rates generic lisdexamfetamine as therapeutically equivalent to brand Vyvanse under its AB rating system. [3] The active moiety after hydrolysis is identical: d-amphetamine. Pharmacokinetic parameters (Cmax, Tmax, AUC) must fall within 80-125% of the reference listed drug to receive AB-rating approval.

When Brand May Still Be Covered

Affinity or any insurer may still cover brand Vyvanse if:

• The prescriber documents a specific medical necessity for the brand (e.g., a patient with known excipient sensitivity to a filler used in the generic formulation).
• All generic alternatives are out of stock nationally (a documented shortage).
• A prior authorization was approved before the generic launched and the plan allows the authorization to run its course.

The HealthRX Prior Authorization Decision Framework for Vyvanse (below) summarizes the clinical and administrative criteria a prescriber should address proactively before submitting a PA to any Medicaid managed-care plan:

HealthRX PA Submission Checklist for Lisdexamfetamine:

• Confirm DSM-5 diagnostic criteria are documented in the medical record with specific symptom count.
• Attach the most recent validated rating scale (ADHD-RS-5, Conners 3, or BRIEF-2).
• Document two prior stimulant trials with doses used, duration, and reason for failure.
• Include cardiovascular screening note (blood pressure, heart rate, absence of structural cardiac disease).
• For patients under 18, include school documentation or teacher rating scale.
• State the specific formulation reason if requesting brand over generic.

How to Appeal a Vyvanse Coverage Denial

A denial is not the end of the process. Federal and New York State law guarantee appeal rights for Medicaid managed-care enrollees.

Internal Appeal

File an internal appeal with Affinity within 60 days of receiving the denial notice. Submit:

• The denial letter from Affinity.
• A letter of medical necessity from the prescriber explaining why Vyvanse or lisdexamfetamine is required.
• Supporting clinical documentation (rating scales, chart notes, prior trial records).
• Any peer-reviewed literature supporting the specific indication.

Affinity must resolve a standard internal appeal within 30 days. An expedited appeal (when the standard timeline would seriously jeopardize the member's health) must be resolved within 72 hours. [8]

External Appeal

If the internal appeal is denied, New York State law allows an external appeal to an independent review organization (IRO) certified by the New York State Department of Financial Services. The IRO decision is binding on the plan. [10]

Fair Hearing

Medicaid enrollees also have the right to request a State Fair Hearing through the New York State Office of Temporary and Disability Assistance (OTDA). Fair hearing requests can be filed by phone (1-800-342-3334) or online. The plan cannot reduce or terminate coverage for the disputed service while the hearing is pending, under "aid-continuing" protections. [1]

Alternative ADHD Medications If Vyvanse Is Not Covered

If Vyvanse coverage is denied and appeals are exhausted, several alternatives are worth discussing with the prescriber.

Generic Mixed Amphetamine Salts (Generic Adderall)

Generic amphetamine salts immediate-release (IR) and extended-release (XR) are Tier 1 preferred on virtually every Medicaid formulary. The generic XR formulation costs under $30/month at most pharmacies. Meta-analyses covering more than 10,000 patients confirm amphetamine salts produce effect sizes for ADHD symptom reduction of approximately 0.6-1.0 standard deviations above placebo. [11]

Methylphenidate Formulations

Generic methylphenidate IR, ER (Concerta generic), and the Daytrana patch are all available. A 2018 Lancet meta-analysis (N=10,068 pediatric patients) found methylphenidate the most evidence-supported medication for children with ADHD based on the balance of efficacy and tolerability data. [12]

Non-Stimulant Options

For patients with contraindications to stimulants (certain cardiac conditions, a history of stimulant-induced psychosis, or documented substance use disorder where stimulant use is clinically inadvisable), non-stimulant options include:

• Atomoxetine (generic Strattera): FDA-approved for ADHD in children, adolescents, and adults. Onset takes 4-6 weeks. A meta-analysis in the Journal of Child Psychology and Psychiatry (N=3,928) found atomoxetine superior to placebo with a standardized mean difference of 0.64 for inattention symptoms. [13]
• Guanfacine ER (generic Intuniv): FDA-approved for ADHD ages 6-17. Often used as adjunct therapy. [14]
• Clonidine ER (generic Kapvay): Another alpha-2 agonist approved for ADHD in children ages 6-17, frequently added to stimulant therapy for residual hyperactivity or sleep disturbance. [14]

Cost Assistance Programs When Coverage Fails

Even without insurance approval, cost-reduction options exist.

Takeda Vyvanse Savings Card

Takeda offers a savings card for commercially insured patients that can reduce out-of-pocket cost to as low as $30/month at participating pharmacies. This program does not apply to Medicaid, Medicare, or other government-funded plans. Eligibility and terms are on the Vyvanse manufacturer website.

GoodRx and Pharmacy Discount Programs

GoodRx and similar platforms negotiate discount pricing at retail pharmacies. For generic lisdexamfetamine 30 mg (30 capsules), GoodRx prices at major chains have ranged from $60-$90. These prices are independent of insurance and can sometimes be lower than the insured copay.

Patient Assistance Programs

Takeda's patient assistance program (Takeda Cares Foundation) may provide brand Vyvanse at no cost to uninsured or underinsured patients who meet income thresholds. Applications require proof of income and a prescriber attestation.

ADHD Diagnosis and Documentation: What Insurers Want to See

Adequate diagnostic documentation is the single most common reason PA requests are approved or denied quickly. The stronger the clinical record, the smoother the PA process.

DSM-5 Criteria Summary

The DSM-5 requires: [5]

• At least 6 of 9 inattention symptoms (5 for adults 17+) OR 6 of 9 hyperactivity-impulsivity symptoms (5 for adults 17+).
• Symptoms present for at least 6 months.
• Several symptoms present before age 12.
• Symptoms present in at least two settings.
• Clear evidence of functional impairment.
• Symptoms not better explained by another mental disorder.

Validated Rating Scales

The ADHD Rating Scale 5th Edition (ADHD-RS-5) is the most widely used clinician-administered tool and produces a total score (0-54 for adults) with normative comparisons. Attaching a completed ADHD-RS-5 to a PA request provides objective evidence reviewers can assess against published norms. [15]

Cardiovascular Screening

The American Heart Association recommends that all children receive a comprehensive cardiovascular history and physical examination before initiating stimulant therapy, though routine ECG is not required in the absence of specific risk factors. [16] Including a brief cardiovascular note in PA documentation demonstrates clinical due diligence and may accelerate approval.

Key Numbers and Contact Information

• Affinity Health Plan Member Services: 1-800-223-6867
• Affinity Pharmacy Benefit Manager: Listed on your pharmacy benefit card; confirm at member portal affinity.org
• New York State Fair Hearing: 1-800-342-3334
• New York State External Appeal: NYS Department of Financial Services, 1-800-400-8882
• Medicaid.gov drug coverage information: https://www.medicaid.gov/medicaid/prescription-drugs/index.html [1]